IASO Pharma Inc.

According to the latest National New Drug Approval Report for 2023 from China's National Medical Products Administration (NMPA), 15 orphan drugs were approved through the regulator's designated priori

Founded six years ago, Shanghai-based, US Nasdaq-listed Gracell Biotechnologies Co. Ltd. is now aiming to bring its lead asset, the dual-targeting CD19 and B-cell maturation antigen (BCMA) CAR-T cel

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. The January J.P. Morgan Healthcare Conf

10 years ago, business talks involving Chinese pharma firms mostly focused on trying to get some attention from established biopharma giants and venture capital investors. The tone today is more on be